PDF(Pubmed)
Abstract：
UNASSIGNED: The National Administration of Traditional Chinese Medicine of the People\'s Republic of China (NATCM) and the State Administration of Traditional Chinese medicine (TCM) advocated a combination therapy of TCM and anti-viral drugs for novel coronavirus pneumonia (NCP) to improve the efficacy of clinical treatment.
UNASSIGNED: Forty-six patients diagnosed with NCP were sequentially divided into intent-to-treat population: the experimental group (combination of FuXi-Tiandi-Wuxing Decoction and anti-viral drugs; n = 23) and the control group (anti-viral drugs only) (n = 23). The two groups were compared in terms of duration of fever, cough symptom score, fatigue, appetite, dyspnea, out-of-bed activities, chest computer tomography (CT) recovery, virological clearance, average length of hospital stay, and clinical effective rate of drug. After 6 days of observation, patients from the control group were divided into as-treated population: experimental subgroup (n = 14) to obtain clinical benefit and control subgroup (n = 9).
UNASSIGNED: There was a significant improvement in the duration of fever (1.087 ± 0.288 vs 4.304 ± 2.490), cough (0.437 ± 0.589 vs 2.435 ± 0.662; P < 0.05), chest CT evaluation (82.6% vs 43.4%; P < 0.05), and virological clearance (60.8% vs 8.7%; P < 0.05) in patients of the experimental group compared with patients in the control group. Further observation in as-treated population reported that cough (0.742 ± 0.463 vs 1.862 ± 0.347; P < 0.05) and fatigue (78.5% vs 33.3%; P < 0.05) were significantly relieved after adding FuXi-Tiandi-Wuxing Decoction to the existing treatment.
UNASSIGNED: An early treatment with combination therapy of FuXi-Tiandi-Wuxing Decoction and anti-viral drugs significantly relieves the clinical symptoms of NCP, shows improvement in chest CT scan, improves virological clearance, shortens average length of hospital stay, and reduces the risk of severe illness. The effect of FuXi-Tiandi-Wuxing Decoction in NCP may be clinically important and require further consideration.
UNASSIGNED: Forty-six patients diagnosed with NCP were sequentially divided into intent-to-treat population: the experimental group (combination of FuXi-Tiandi-Wuxing Decoction and anti-viral drugs; n = 23) and the control group (anti-viral drugs only) (n = 23). The two groups were compared in terms of duration of fever, cough symptom score, fatigue, appetite, dyspnea, out-of-bed activities, chest computer tomography (CT) recovery, virological clearance, average length of hospital stay, and clinical effective rate of drug. After 6 days of observation, patients from the control group were divided into as-treated population: experimental subgroup (n = 14) to obtain clinical benefit and control subgroup (n = 9).
UNASSIGNED: There was a significant improvement in the duration of fever (1.087 ± 0.288 vs 4.304 ± 2.490), cough (0.437 ± 0.589 vs 2.435 ± 0.662; P < 0.05), chest CT evaluation (82.6% vs 43.4%; P < 0.05), and virological clearance (60.8% vs 8.7%; P < 0.05) in patients of the experimental group compared with patients in the control group. Further observation in as-treated population reported that cough (0.742 ± 0.463 vs 1.862 ± 0.347; P < 0.05) and fatigue (78.5% vs 33.3%; P < 0.05) were significantly relieved after adding FuXi-Tiandi-Wuxing Decoction to the existing treatment.
UNASSIGNED: An early treatment with combination therapy of FuXi-Tiandi-Wuxing Decoction and anti-viral drugs significantly relieves the clinical symptoms of NCP, shows improvement in chest CT scan, improves virological clearance, shortens average length of hospital stay, and reduces the risk of severe illness. The effect of FuXi-Tiandi-Wuxing Decoction in NCP may be clinically important and require further consideration.
摘要：
国家概述：中华人民共和国国家中医药管理局（NATCM）和国家中医药管理局（TCM）倡导中药和抗病毒药物联合治疗新型冠状病毒肺炎（NCP），以提高临床治疗效果。
UNASSIGNED：将诊断为NCP的46例患者依次分为意向治疗人群：实验组（复喜天地五兴汤联合抗病毒药物；n=23）和对照组（仅抗病毒药物）（n=23）。比较两组患者的发热持续时间,咳嗽症状评分,疲劳,食欲,呼吸困难,下床活动,胸部计算机断层扫描（CT）恢复，病毒学清除,平均住院时间,药物的临床有效率。经过6天的观察，对照组的患者被分为接受治疗的人群:获得临床获益的实验亚组(n=14)和对照组(n=9).
未经评估：发热持续时间有显著改善（1.087±0.288vs4.304±2.490），咳嗽（0.437±0.589vs2.435±0.662；P<0.05），胸部CT评价（82.6%vs43.4%；P<0.05），与对照组相比，实验组患者的病毒学清除率（60.8％vs8.7％；P<0.05）。在接受治疗的人群中进一步观察，咳嗽（0.742±0.463vs1.862±0.347；P<0.05）和疲劳（78.5％vs33.3％；P<0.05）在现有治疗基础上明显缓解。
UNASSIGNED：复喜天地五兴汤联合抗病毒药物的早期治疗可明显缓解NCP的临床症状，显示胸部CT扫描的改善，提高病毒学清除，缩短平均住院时间,并降低患严重疾病的风险。复喜天地五行汤在NCP中的作用可能具有临床意义，需要进一步考虑。
UNASSIGNED：将诊断为NCP的46例患者依次分为意向治疗人群：实验组（复喜天地五兴汤联合抗病毒药物；n=23）和对照组（仅抗病毒药物）（n=23）。比较两组患者的发热持续时间,咳嗽症状评分,疲劳,食欲,呼吸困难,下床活动,胸部计算机断层扫描（CT）恢复，病毒学清除,平均住院时间,药物的临床有效率。经过6天的观察，对照组的患者被分为接受治疗的人群:获得临床获益的实验亚组(n=14)和对照组(n=9).
未经评估：发热持续时间有显著改善（1.087±0.288vs4.304±2.490），咳嗽（0.437±0.589vs2.435±0.662；P<0.05），胸部CT评价（82.6%vs43.4%；P<0.05），与对照组相比，实验组患者的病毒学清除率（60.8％vs8.7％；P<0.05）。在接受治疗的人群中进一步观察，咳嗽（0.742±0.463vs1.862±0.347；P<0.05）和疲劳（78.5％vs33.3％；P<0.05）在现有治疗基础上明显缓解。
UNASSIGNED：复喜天地五兴汤联合抗病毒药物的早期治疗可明显缓解NCP的临床症状，显示胸部CT扫描的改善，提高病毒学清除，缩短平均住院时间,并降低患严重疾病的风险。复喜天地五行汤在NCP中的作用可能具有临床意义，需要进一步考虑。
